While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...
GlaxoSmithKline (GSK) appears to be focusing more on finding a new CEO than any large M&A deals after last year's $20 billion asset swap with Novartis, according to a briefing following strong ...
GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines. While GSK already agreed to multiple deals in ...
Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.
Kennedy Jr. to run the Department of Health and Human Services. How do Sanofi CEO Paul Hudson and GSK CEO Emma Walmsley—who lead two of the top vaccine companies in the world—feel about the ...
GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio in the US, their overall drug pipeline and working with Robert F.
Nitin Sahney, co-founder and CEO of PharmaCord, poses for a portrait in the pharmaceutical support company’s new headquarters ...
GSK CEO Emma Walmsley publicly urged the industry to “run towards” conversations about vaccine efficacy, emphasizing transparency, trust, and open dialogue. Her call to action aligns with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback